The US Food and Drug
Administration (FDA) has
issued a warning that a case of
definite progressive multifocal
leukoencephalopathy (PML) and a
case of probable PML have been
reported in patients taking Gilenya
(fingolimod) for multiple sclerosis.
These are the first such cases
associated with Gilenya and the
information about these cases will
be added to the drug label, the FDA
said - CLICK HERE for moreThe above article was sent to subscribers in Pharmacy Daily's issue from 06 Aug 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Aug 15
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.